Current and Emerging Therapies for Advanced Adrenocortical Carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
2002, NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”), NIH Consens State Sci Statements, 19, 1
Allolio, 2006, Clinical review: Adrenocortical carcinoma: Clinical update, J Clin Endocrinol Metab, 91, 2027, 10.1210/jc.2005-2639
Wooten, 1993, Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature, Cancer, 72, 3145, 10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N
Wajchenberg, 2000, Adrenocortical carcinoma: Clinical and laboratory observations, Cancer, 88, 711, 10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W
Schteingart, 2005, Management of patients with adrenal cancer: Recommendations of an international consensus conference, Endocr Relat Cancer, 12, 667, 10.1677/erc.1.01029
Luton, 1990, Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy, N Engl J Med, 322, 1195, 10.1056/NEJM199004263221705
Icard, 1992, Survival rates and prognostic factors in adrenocortical carcinoma, World J Surg, 16, 753, 10.1007/BF02067377
Icard, 2001, Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group, World J Surg, 25, 891, 10.1007/s00268-001-0047-y
Terzolo, 2007, Adjuvant mitotane treatment for adrenocortical carcinoma, N Engl J Med, 356, 2372, 10.1056/NEJMoa063360
Soon, 2008, Molecular markers and the pathogenesis of adrenocortical cancer, The Oncologist, 13, 548, 10.1634/theoncologist.2007-0243
Abiven, 2006, Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients, J Clin Endocrinol Metab, 91, 2650, 10.1210/jc.2005-2730
Berruti, 2005, Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial, Endocr Relat Cancer, 12, 657, 10.1677/erc.1.01025
Henley, 1983, Adrenal cortical carcinoma—a continuing challenge, Surgery, 94, 926
Cohn, 1986, Adrenocortical carcinoma, Surgery, 100, 1170
Macfarlane, 1958, Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases, Ann R Coll Surg Engl, 23, 155
Lee, 1995, Surgical management, DNA content, and patient survival in adrenal cortical carcinoma, Surgery, 118, 1090, 10.1016/S0039-6060(05)80119-9
DeLellis, 2004, Pathology and Genetics of Tumours of Endocrine Organs, 1
Fassnacht, 2009, Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification, Cancer, 115, 243, 10.1002/cncr.24030
Lughezzani, 2010, The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer staging system: A North American validation, Eur J Cancer, 46, 713, 10.1016/j.ejca.2009.12.007
Veytsman, 2009, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma, J Clin Oncol, 27, 4619, 10.1200/JCO.2008.17.2775
Berruti, 2010, Adjuvant therapy in patients with adrenocortical carcinoma: A position of an international panel, J Clin Oncol, 28, e401, 10.1200/JCO.2009.27.5958
Giordano, 2003, Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis, Am J Pathol, 162, 521, 10.1016/S0002-9440(10)63846-1
Fraipont, 2005, Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy, J Clin Endocrinol Metab, 90, 1819, 10.1210/jc.2004-1075
Velázquez-Fernández, 2005, Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy, Surgery, 138, 1087, 10.1016/j.surg.2005.09.031
Reyniès, 2009, Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival, J Clin Oncol, 27, 1108, 10.1200/JCO.2008.18.5678
Giordano, 2009, Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling, Clin Cancer Res, 15, 668, 10.1158/1078-0432.CCR-08-1067
Soon, 2009, Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas, Endocr Relat Cancer, 16, 573, 10.1677/ERC-08-0237
Laurell, 2009, Transcriptional profiling enables molecular classification of adrenocortical tumours, Eur J Endocrinol, 161, 141, 10.1530/EJE-09-0068
Fassnacht, 2009, New targets and therapeutic approaches for endocrine malignancies, Pharmacol Ther, 123, 117, 10.1016/j.pharmthera.2009.03.013
Khorram-Manesh, 1998, Adrenocortical carcinoma: Surgery and mitotane for treatment and steroid profiles for follow-up, World J Surg, 22, 605, 10.1007/s002689900442
Kendrick, 2001, Adrenocortical carcinoma: Surgical progress or status quo?, Arch Surg, 136, 543, 10.1001/archsurg.136.5.543
Crucitti, 1996, The Italian Registry for Adrenal Cortical Carcinoma: Analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group, Surgery, 119, 161, 10.1016/S0039-6060(96)80164-4
Schulick, 1999, Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma, Ann Surg Oncol, 6, 719, 10.1007/s10434-999-0719-7
Grubbs, 2010, Recurrence of adrenal cortical carcinoma following resection: Surgery alone can achieve results equal to surgery plus mitotane, Ann Surg Oncol, 17, 263, 10.1245/s10434-009-0716-x
Miller, 2010, Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma, World J Surg, 34, 1380, 10.1007/s00268-010-0532-2
Leboulleux, 2010, Adrenocortical carcinoma: Is the surgical approach a risk factor of peritoneal carcinomatosis?, Eur J Endocrinol, 162, 1147, 10.1530/EJE-09-1096
Ng, 2003, Adrenocortical carcinoma: Diagnosis, evaluation and treatment, J Urol, 169, 5, 10.1016/S0022-5347(05)64023-2
Allolio, 2004, Management of adrenocortical carcinoma, Clin Endocrinol (Oxf), 60, 273, 10.1046/j.1365-2265.2003.01881.x
Henry, 2002, Results of laparoscopic adrenalectomy for large and potentially malignant tumors, World J Surg, 26, 1043, 10.1007/s00268-002-6666-0
Kebebew, 2002, Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms, Arch Surg, 137, 948, 10.1001/archsurg.137.8.948
Lombardi, 2006, Role of laparoscopy in the management of adrenal malignancies, J Surg Oncol, 94, 128, 10.1002/jso.20599
Palazzo, 2006, Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors, World J Surg, 30, 893, 10.1007/s00268-005-0288-2
Gagner, 1992, Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma, N Engl J Med, 327, 1033, 10.1056/NEJM199210013271417
Gill, 2001, The case for laparoscopic adrenalectomy, J Urol, 166, 429, 10.1016/S0022-5347(05)65958-7
Soon, 2008, Laparoscopic surgery is safe for large adrenal lesions, Eur J Surg Oncol, 34, 67, 10.1016/j.ejso.2007.03.007
Ushiyama, 1997, A case of Cushing's syndrome due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy, J Urol, 157, 2239, 10.1016/S0022-5347(01)64729-3
Zeh, 2003, One hundred laparoscopic adrenalectomies: A single surgeon's experience, Ann Surg Oncol, 10, 1012, 10.1245/ASO.2003.06.001
Prager, 2004, Applicability of laparoscopic adrenalectomy in a prospective study in 150 consecutive patients, Arch Surg, 139, 46, 10.1001/archsurg.139.1.46
Gonzalez, 2005, Laparoscopic resection of adrenal cortical carcinoma: A cautionary note, Surgery, 138, 1078, 10.1016/j.surg.2005.09.012
Cobb, 2005, Laparoscopic adrenalectomy for malignancy, Am J Surg, 189, 405, 10.1016/j.amjsurg.2005.01.021
Brix, 2010, Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: Surgical and oncologic outcome in 152 patients, Eur Urol, 58, 609, 10.1016/j.eururo.2010.06.024
Pommier, 1992, An eleven-year experience with adrenocortical carcinoma, Surgery, 112, 963
Jensen, 1991, Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy, Arch Surg, 126, 457, 10.1001/archsurg.1991.01410280059008
Icard, 1992, Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery, Surgery, 112, 972
Bellantone, 1997, Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma, Surgery, 122, 1212, 10.1016/S0039-6060(97)90229-4
Zografos, 1994, Adrenal adenocarcinoma: A review of 53 cases, J Surg Oncol, 55, 160, 10.1002/jso.2930550306
Nelson, 1949, Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE), Arch Pathol (Chic), 48, 387
Hahner, 2005, Mitotane for adrenocortical carcinoma treatment, Curr Opin Investig Drugs, 6, 386
Schteingart, 2000, Conventional and novel strategies in the treatment of adrenocortical cancer, Braz J Med Biol Res, 33, 1197, 10.1590/S0100-879X2000001000009
Pineiro-Sanchez, 1995, Synthesis of B3H-mitotane for use in a rapid assay for mitotane metabolism, J Labelled Comp Radiopharm, 36, 121, 10.1002/jlcr.2580360204
Reif, 1974, Aromatic hydroxylation and alkyl oxidation in metabolism of mitotane (o,p'-DDD) in humans, J Pharm Sci, 63, 1730, 10.1002/jps.2600631113
Schteingart, 1993, Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma, Cancer Chemother Pharmacol, 31, 459, 10.1007/BF00685036
Cai, 1995, Metabolic activation and binding of mitotane in adrenal cortex homogenates, J Pharm Sci, 84, 134, 10.1002/jps.2600840203
Slooten, 1984, The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic implications of serum level monitoring, Eur J Cancer Clin Oncol, 20, 47, 10.1016/0277-5379(84)90033-6
Haak, 1994, Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients, Br J Cancer, 69, 947, 10.1038/bjc.1994.183
Baudin, 2001, Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma, Cancer, 92, 1385, 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2
Wängberg, 2010, The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane, Endocr Relat Cancer, 17, 265, 10.1677/ERC-09-0190
Terzolo, 2000, Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer, J Clin Endocrinol Metab, 85, 2234
Faggiano, 2006, Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: Preliminary results, Clin Endocrinol (Oxf), 64, 110, 10.1111/j.1365-2265.2005.02403.x
Berruti, 2008, Emerging drugs for adrenocortical carcinoma, Exp Opin Emerg Drugs, 13, 497, 10.1517/14728214.13.3.497
Seters, 1991, Mitotane increases the blood levels of hormone-binding proteins, Acta Endocrinol (Copenh), 124, 526, 10.1530/acta.0.1240526
Nader, 2006, Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans, J Clin Endocrinol Metab, 91, 2165, 10.1210/jc.2005-2157
Alexandraki, 2010, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: A pilot study, Clin Endocrinol (Oxf), 72, 305, 10.1111/j.1365-2265.2009.03631.x
Zatelli, 2010, Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model, Endocrinology, 151, 2453, 10.1210/en.2009-1404
Terzolo, 2008, Adjunctive treatment of adrenocortical carcinoma, Curr Opin Endocrinol Diabetes Obes, 15, 221, 10.1097/MED.0b013e3282fdf4c0
Robinson, 1987, The effect of o,p'-DDD on adrenal steroid replacement therapy requirements, Clin Endocrinol (Oxf), 27, 437, 10.1111/j.1365-2265.1987.tb01171.x
Hague, 1989, Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma, Clin Endocrinol (Oxf), 31, 51, 10.1111/j.1365-2265.1989.tb00453.x
Kasperlik-Zaluska, 2000, Clinical results of the use of mitotane for adrenocortical carcinoma, Braz J Med Biol Res, 33, 1191, 10.1590/S0100-879X2000001000008
Flynn, 1992, P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma, Surgery, 112, 981
Haak, 1993, Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer, Eur J Cancer, 29A, 1036, 10.1016/S0959-8049(05)80219-9
Bates, 1991, Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas, J Clin Endocrinol Metab, 73, 18, 10.1210/jcem-73-1-18
Feller, 1997, A patient with adrenocortical carcinoma: Characterization of its biological activity and drug resistance profile, Clin Cancer Res, 3, 389
Abraham, 2002, A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist, Cancer, 94, 2333, 10.1002/cncr.10487
Olaussen, 2006, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570
Ronchi, 2009, Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy, Endocr Relat Cancer, 16, 907, 10.1677/ERC-08-0224
Berruti, 1998, Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer, Cancer, 83, 2194, 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3
Khan, 2000, Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use, Ann Oncol, 11, 1281, 10.1023/A:1008377915129
Khan, 2004, Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer, Med Oncol, 21, 167, 10.1385/MO:21:2:167
Sperone, 2010, Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: A multicenter phase II study, Endocr Relat Cancer, 17, 445, 10.1677/ERC-09-0281
Fallo, 1998, Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line, Chemotherapy, 44, 129, 10.1159/000007104
Montoya, 2008, Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture, Horm Metab Res, 40, 302, 10.1055/s-2008-1073139
Schneider, 2007, A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors, Cancer Chemother Pharmacol, 59, 261, 10.1007/s00280-006-0264-z
Suh, 2010, Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells, Arch Surg, 145, 226, 10.1001/archsurg.2009.292
Hermsen, 2010, Response to radiation therapy in adrenocortical carcinoma, J Endocrinol Invest, 33, 712, 10.1007/BF03346675
Cerquetti, 2008, Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines, Endocrine-Related Cancer, 15, 623, 10.1677/erc.1.1315
Cerquetti, 2010, Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation, Int J Oncol, 37, 493
Khan, 2003, 11C-metomidate PET imaging of adrenocortical cancer, Eur J Nucl Med Mol Imaging, 30, 403, 10.1007/s00259-002-1025-9
Hennings, 2006, [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings, J Clin Endocrinol Metab, 91, 1410, 10.1210/jc.2005-2273
Hahner, 2008, [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes, J Clin Endocrinol Metab, 93, 2358, 10.1210/jc.2008-0050
Wood, 2003, Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases, Cancer, 97, 554, 10.1002/cncr.11084
Pacella, 2008, Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma, Eur J Radiol, 66, 88, 10.1016/j.ejrad.2007.04.009
Bauditz, 2009, Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer—a case report and review of the literature, Exp Clin Endocrinol Diabetes, 117, 316, 10.1055/s-0028-1087178
Venkatesan, 2010, Percutaneous ablation of adrenal tumors, Tech Vasc Interv Radiol, 13, 89, 10.1053/j.tvir.2010.02.004
Shalet, 2008, Pharmacological treatment of hypercortisolism, Curr Opin Endocrinol Diabetes Obes, 15, 234, 10.1097/MED.0b013e3282fc7025
Fassnacht, 2009, Clinical management of adrenocortical carcinoma, Best Pract Res Clin Endocrinol Metab, 23, 273, 10.1016/j.beem.2008.10.008
Pont, 1982, Ketoconazole blocks adrenal steroid synthesis, Ann Intern Med, 97, 370, 10.7326/0003-4819-97-3-370
Kowal, 1983, The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells, Endocrinology, 112, 1541, 10.1210/endo-112-4-1541
Loose, 1983, Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes, J Clin Invest, 71, 1495, 10.1172/JCI110903
Van Tyle, 1984, Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use, Pharmacotherapy, 4, 343, 10.1002/j.1875-9114.1984.tb03398.x
Loose, 1983, Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells, J Clin Invest, 72, 404, 10.1172/JCI110982
Verhelst, 1991, Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome, Clin Endocrinol (Oxf), 35, 169, 10.1111/j.1365-2265.1991.tb03517.x
Misbin, 1976, Aminoglutethimide in the treatment of Cushing's syndrome, J Clin Pharmacol, 16, 645, 10.1002/j.1552-4604.1976.tb01504.x
Fassnacht, 2000, New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line, Eur J Clin Invest, 30, 76, 10.1046/j.1365-2362.2000.0300s3076.x
Wagner, 1984, Inhibition of adrenal steroidogenesis by the anesthetic etomidate, N Engl J Med, 310, 1415, 10.1056/NEJM198405313102202
Kirschner, 2006, Emerging treatment strategies for adrenocortical carcinoma: A new hope, J Clin Endocrinol Metab, 91, 14, 10.1210/jc.2005-1739
Gicquel, 1994, Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors, J Clin Endocrinol Metab, 78, 1444
Gicquel, 2001, Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors, Cancer Res, 61, 6762
Schmitt, 2006, IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours, Histopathology, 49, 298, 10.1111/j.1365-2559.2006.02505.x
Almeida, 2008, Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors, J Clin Endocrinol Metab, 93, 3524, 10.1210/jc.2008-0065
Weber, 2000, The role of the insulin-like growth factor system in adrenocortical tumourigenesis, Eur J Clin Invest, 30, 69, 10.1046/j.1365-2362.2000.0300s3069.x
Tao, 2007, Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer, Nat Clin Pract Oncol, 4, 591, 10.1038/ncponc0934
Gualberto, 2009, Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions, Oncogene, 28, 3009, 10.1038/onc.2009.172
Logié, 1999, Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line, J Mol Endocrinol, 23, 23, 10.1677/jme.0.0230023
Barlaskar, 2009, Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma, J Clin Endocrinol Metab, 94, 204, 10.1210/jc.2008-1456
Haluska, 2010, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma, Cancer Chemother Pharmacol, 65, 765, 10.1007/s00280-009-1083-9
Carden, 2009, Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors, J Clin Oncol, 27, 3544, 10.1200/jco.2009.27.15_suppl.3544
Kamio, 1990, Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma, Hum Pathol, 21, 277, 10.1016/0046-8177(90)90227-V
Sasano, 1994, Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization, Mod Pathol, 7, 741
Edgren, 1997, Biological characteristics of adrenocortical carcinoma: A study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas, Anticancer Res, 17, 1303
Nakamura, 2009, An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma, Endocr Pathol, 20, 17, 10.1007/s12022-009-9058-2
Samnotra, 2007, A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC), J Clin Oncol, 25, 15527, 10.1200/jco.2007.25.18_suppl.15527
Quinkler, 2008, Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine, J Clin Endocrinol Metab, 93, 2057, 10.1210/jc.2007-2564
Eichholz, 2010, Anti-angiogenesis therapies: Their potential in cancer management, Onco Targets Ther, 3, 69
Fraipont, 2000, Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: Correlation with genotypic alterations, J Clin Endocrinol Metab, 85, 4734
Bernini, 2002, Angiogenesis in human normal and pathologic adrenal cortex, J Clin Endocrinol Metab, 87, 4961, 10.1210/jc.2001-011799
Zacharieva, 2004, Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours, Eur J Endocrinol, 150, 345, 10.1530/eje.0.1500345
Britvin, 2005, Vascular endothelium growth factor in the sera of patients with adrenal tumors, Bull Exp Biol Med, 140, 228, 10.1007/s10517-005-0452-6
Kolomecki, 2000, Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours, Cytobios, 101, 55
Kolomecki, 2001, Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours, Endocr Regul, 35, 9
Wortmann, 2010, Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma, Eur J Endocrinol, 162, 349, 10.1530/EJE-09-0804
Chacón, 2005, CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide, J Clin Oncol, 23, 1579, 10.1200/JCO.2005.03.195
Siemann, 2011, The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents, Cancer Treat Rev, 37, 63, 10.1016/j.ctrv.2010.05.001
Hong, 2009, Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin Cancer Res, 15, 7061, 10.1158/1078-0432.CCR-09-1241
Butler, 2010, Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma, Endocr Pract, 16, 441, 10.4158/EP09295.CR
Lee, 2009, Metastatic adrenocortical carcinoma treated with sunitinib: A case report, Jpn J Clin Oncol, 39, 183, 10.1093/jjco/hyn146
Gross, 2006, The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R, Endocr Relat Cancer, 13, 535, 10.1677/erc.1.01124
Del Bufalo, 2006, Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus, Cancer Res, 66, 5549, 10.1158/0008-5472.CAN-05-2825
Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor, Nat Med, 8, 128, 10.1038/nm0202-128
Humar, 2002, Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling, FASEB J, 16, 771, 10.1096/fj.01-0658com
Bruns, 2004, Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer, Clin Cancer Res, 10, 2109, 10.1158/1078-0432.CCR-03-0502
Doghman, 2010, Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors, Cancer Res, 70, 4666, 10.1158/0008-5472.CAN-09-3970
Takara, 2006, An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy, Curr Pharm Des, 12, 273, 10.2174/138161206775201965
Gottesman, 2002, Multidrug resistance in cancer: Role of ATP-dependent transporters, Nat Rev Cancer, 2, 48, 10.1038/nrc706
Fridborg, 1994, P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells, Anticancer Res, 14, 1009
Bates, 2001, A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar), Cancer, 92, 1577, 10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H
Bates, 2004, A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma, Clin Cancer Res, 10, 4724, 10.1158/1078-0432.CCR-0829-03
Carlson, 2006, A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the Eastern Cooperative Oncology Group, Cancer Invest, 24, 677, 10.1080/07357900600981349
Fox, 2007, Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor, Expert Rev Anticancer Ther, 7, 447, 10.1586/14737140.7.4.447
Kuruba, 2008, Current management of adrenal tumors, Curr Opin Oncol, 20, 34, 10.1097/CCO.0b013e3282f301fd
Ferruzzi, 2005, Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R, J Clin Endocrinol Metab, 90, 1332, 10.1210/jc.2004-0978
Betz, 2005, Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation, J Clin Endocrinol Metab, 90, 3886, 10.1210/jc.2004-1267
Cantini, 2008, Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling, PPAR Res, 2008, 904041, 10.1155/2008/904041
Luconi, 2010, Rosiglitazone impairs proliferation of human adrenocortical cancer: Preclinical study in a xenograft mouse model, Endocr Relat Cancer, 17, 169, 10.1677/ERC-09-0170
Ondrey, 2009, Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: Implications for chemoprevention, Clin Cancer Res, 15, 2, 10.1158/1078-0432.CCR-08-0326
Tissier, 2005, Mutations of beta-catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors, Cancer Res, 65, 7622, 10.1158/0008-5472.CAN-05-0593
Gaujoux, 2008, Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors, J Clin Endocrinol Metab, 93, 4135, 10.1210/jc.2008-0631
Tadjine, 2008, Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas, Clin Endocrinol (Oxf), 68, 264, 10.1111/j.1365-2265.2007.03033.x
Berthon, 2010, Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development, Hum Mol Genet, 19, 1561, 10.1093/hmg/ddq029
Doghman, 2008, The T cell factor/beta-catenin antagonist PKF115–584 inhibits proliferation of adrenocortical carcinoma cells, J Clin Endocrinol Metab, 93, 3222, 10.1210/jc.2008-0247
Schimmer, 2010, Minireview: Steroidogenic factor 1: Its roles in differentiation, development, and disease, Mol Endocrinol, 24, 1322, 10.1210/me.2009-0519
Figueiredo, 2005, Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors, J Clin Endocrinol Metab, 90, 615, 10.1210/jc.2004-0942
Pianovski, 2006, SF-1 overexpression in childhood adrenocortical tumours, Eur J Cancer, 42, 1040, 10.1016/j.ejca.2006.01.022
Doghman, 2007, Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer, Mol Endocrinol, 21, 2968, 10.1210/me.2007-0120